Angiogenesis in multiple myeloma
- 31 July 2006
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 42 (11), 1581-1590
- https://doi.org/10.1016/j.ejca.2006.02.017
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Circulating endothelial progenitor cells in multiple myeloma: implications and significanceBlood, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Serum syndecan‐1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the diseaseEuropean Journal of Haematology, 2004
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Syndecan-1 Expression on Malignant Cells from the Blood and Marrow of Patients with Plasma Cell Proliferative Disorders and B-Cell Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1998
- Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluationEuropean Journal Of Cancer, 1996
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growthNature, 1987